Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cells

26 May 2024

Abstract excerpt

Drug resistance is the primary contributor to the high mortality rate of ovarian cancer (OC). The loss of BRCA1/2 function is linked to drug sensitivity in OC cells. The aim of this study is to enhance the drug sensitivity of OC cells by inducing BRCA1 dysfunction through promoter epigenetic editing. Epigenetic regulatory regions within the BRCA1 promoter, affecting gene expression, were initially discerned...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to PARP inhibition in cancer therapy
Share to Plant Virus Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38796857
DOI: 10.1080/15592294.2024.2357518

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic editing of BRCA1 promoter increases cisplatin and olaparib sensitivity of ovarian cancer cellsPMID 38796857Read ↗

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editingSemantic proximity Read ↗

Exploiting epigenetic dependencies in ovarian cancer therapySemantic proximity Read ↗

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapySemantic proximity Read ↗

<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancerSemantic proximity Read ↗

DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatmentSemantic proximity Read ↗

A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.Semantic proximity Read ↗

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read ↗

Construction and validation of a robust epigenetic gene-set based signature in ovarian cancerSemantic proximity Read ↗

Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer.Semantic proximity Read ↗

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)Semantic proximity Read ↗

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancerSemantic proximity Read ↗

BRCA1 promoter methylation predicts adverse ovarian cancer prognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.